1CL7
ANTI HIV1 PROTEASE FAB
1CL7 の概要
| エントリーDOI | 10.2210/pdb1cl7/pdb |
| 分子名称 | PROTEIN (IGG1 ANTIBODY 1696 (light chain)), PROTEIN (IGG1 ANTIBODY 1696 (variable heavy chain)), PROTEIN (IGG1 ANTIBODY 1696 (constant heavy chain)) (3 entities in total) |
| 機能のキーワード | fab fragment, cross-reactivity, hiv1 protease, enzyme inhibition, immunoglobulin, immune system |
| 由来する生物種 | Mus musculus (house mouse) 詳細 |
| 細胞内の位置 | Cell membrane; Single-pass membrane protein (Potential): P01869 |
| タンパク質・核酸の鎖数 | 3 |
| 化学式量合計 | 47660.99 |
| 構造登録者 | |
| 主引用文献 | Lescar, J.,Brynda, J.,Rezacova, P.,Stouracova, R.,Riottot, M.M.,Chitarra, V.,Fabry, M.,Horejsi, M.,Sedlacek, J.,Bentley, G.A. Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci., 8:2686-2696, 1999 Cited by PubMed Abstract: The monoclonal antibody 1696, directed against the HIV-1 protease, displays strong inhibitory effects toward the catalytic activity of the enzyme of both the HIV-1 and HIV-2 isolates. This antibody cross-reacts with peptides that include the N-terminus of the enzyme, a region that is well conserved in sequence among different viral strains and which, furthermore, is crucial for homodimerization to the active enzymatic form. This observation, as well as antigen-binding studies in the presence of an active site inhibitor, suggest that 1696 inhibits the HIV protease by destabilizing its active homodimeric form. To characterize further how the antibody 1696 inhibits the HIV-1 and HIV-2 proteases, we have solved the crystal structure of its Fab fragment by molecular replacement and refined it at 3.0 A resolution. The antigen binding site has a deep cavity at its center, which is lined mainly by acidic and hydrophobic residues, and is large enough to accommodate several antigen residues. The structure of the Fab 1696 could form a starting basis for the design of alternative HIV protease-inhibiting molecules of broad specificity. PubMed: 10631984主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (3 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






